DaleySF, AliMA, OhnumaT, et al.Anorexia and Cachexia. In: StatPearls. Treasure Island (FL): StatPearls Publishing; January 19, 2025. Available from: https://www.ncbi.nlm.nih.gov/books/NBK430977/ [Last accessed: June23, 2025].
2.
RoelandEJ, BohlkeK, BaracosVE, et al.; Cancer Cachexia Expert Panel. Cancer Cachexia: ASCO Guideline Rapid Recommendation Update. J Clin Oncol, 2023; 41(25):4178–4179.
3.
SandhyaL, Devi SreenivasanN, GoenkaL, et al.Randomized double-blind placebo-controlled study of olanzapine for chemotherapy-related anorexia in patients with locally advanced or metastatic gastric, hepatopancreaticobiliary, and lung cancer. J Clin Oncol, 2023; 41(14):2617–2627.
4.
NavariRM, PywellCM, Le-RademacherJG, et al.Olanzapine for the Treatment of Advanced Cancer-Related Chronic Nausea and/or Vomiting: A Randomized Pilot Trial. JAMA Oncol, 2020; 6(6):895–899.
5.
MoertelCG, SchuttAJ, ReitemeierRJ, et al.Corticosteroid therapy of preterminal gastrointestinal cancer. Cancer, 1974 Jun;33(6):1607–1609.
6.
BrueraE, RocaE, CedaroL, et al.Action of oral methylprednisolone in terminal cancer patients: A prospective randomized double-blind study. Cancer Treat Rep, 1985; 69(7–8):751–754.
7.
YavuzsenT, DavisMP, WalshD, et al.Systematic review of the treatment of cancer-associated anorexia and weight loss. J Clin Oncol, 2005; 23(33):8500–8511.
8.
BealJE, OlsonR, LaubensteinL, et al.Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS. J Pain Symptom Manage, 1995; 10(2):89–97.
9.
JatoiA, WindschitlHE, LoprinziCL, et al.Dronabinol versus megestrol acetate versus combination therapy for cancer-associated anorexia: A North Central Cancer Treatment Group study. J Clin Oncol, 2002; 20(2):567–573.
10.
LoprinziCL, SchaidDJ, DoseAM, et al.Body-composition changes in patients who gain weight while receiving megestrol acetate. J Clin Oncol, 1993; 11(1):152–154.
11.
WeisbergJ, WangerJ, OlsonJ, et al.Megestrol acetate stimulates weight gain and ventilation in underweight COPD patients. Chest, 2002; 121(4):1070–1078.
12.
Ruiz GarciaV, López-BrizE, Carbonell SanchisR, et al.Megestrol acetate for treatment of anorexia-cachexia syndrome. Cochrane Database Syst Rev, 2013; 2013(3):Cd004310.
13.
LoprinziCL, MichalakJC, SchaidDJ, et al.Phase III evaluation of four doses of megestrol acetate as therapy for patients with cancer anorexia and/or cachexia. J Clin Oncol, 1993; 11(4):762–767.
14.
WatanabeN, OmoriIM, NakagawaA, et al.Mirtazapine versus other antidepressive agents for depression. Cochrane Database Syst Rev, 2011(12):CD006528.
15.
LaimerM, Kramer-ReinstadlerK, RauchenzaunerM, et al.Effect of mirtazapine treatment on body composition and metabolism. J Clin Psychiatry, 2006; 67(3):421–424.
16.
RiechelmannRP, BurmanD, TannockIF, et al.Phase II trial of mirtazapine for cancer-related cachexia and anorexia. Am J Hosp Palliat Care, 2010; 27(2):106–110.
17.
HunterCN, Abdel-AalHH, ElsheriefWA, et al.Mirtazapine in cancer-associated anorexia and cachexia: A double-blind placebo-controlled randomized trial. J Pain Symptom Manage, 2021; 62(6):1207–1215.
18.
ArrietaO, Cárdenas-FernándezD, Rodriguez-MayoralO, et al.Mirtazapine as appetite stimulant in patients with non-small cell lung cancer and anorexia: A randomized clinical trial. JAMA Oncol, 2024; 10(3):305–314.
19.
SolheimTS, FearonKC, BlumD, et al.Non-steroidal anti-inflammatory treatment in cancer cachexia: A systematic literature review. Acta Oncol, 2013; 52(1):6–17.
20.
MaYJ, YuJ, XiaoJ, et al.The consumption of omega-3 polyunsaturated fatty acids improves clinical outcomes and prognosis in pancreatic cancer patients: A systematic evaluation. Nutr Cancer, 2015; 67(1):112–118.
21.
GroarkeJD, CrawfordJ, CollinsSM, et al.Ponsegromab for the treatment of cancer cachexia. N Engl J Med, 2024; 391(24):2291–2303.
